# Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

> **NCT04641442** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

## Interventions

- **BIOLOGICAL:** MAS825
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04641442
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-18
- **Primary completion:** 2025-10-14
- **Final completion:** 2032-04-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641442, "Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04641442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*